Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5679272 | 0.85 | KMT2A (0.41) | MEN1KMT2ACYP2D6ALDH1A1MAPT | |
| SCHEMBL29980766 | 0.84 | ACHE (0.39) | MEN1KMT2AALDH1A1MAPTPKM | |
| SCHEMBL29284822 | 0.83 | MEN1 (0.52) | MEN1KMT2AADAM17ALDH1A1HPGD | |
| SCHEMBL5870619 | 0.83 | MEN1 (0.54) | MEN1KMT2AADAM17ALDH1A1KDM4E | |
| SCHEMBL8061919 | 0.75 | VDR (0.47) | MEN1KMT2AALDH1A1L3MBTL1HTT | |
| SCHEMBL14991279 | 0.75 | AMY1A (0.44) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL30716894 | 0.75 | AMY1A (0.44) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL18613992 | 0.74 | CA12 (0.39) | MEN1KMT2ACYP2D6ALDH1A1L3MBTL1 | |
| SCHEMBL2486732 | 0.74 | CYP2D6 (0.39) | MEN1KMT2ACYP2D6ALDH1A1MAPT | |
| SCHEMBL16619075 | 0.74 | CA12 (0.39) | MEN1KMT2ACYP2D6ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667473-A2 | PROCESS FOR PREPARING 2-EXO-(2-METHYLBENZYLOXY)-1-METHYL-4-ISOPROPYL-7-OXABICYCLO[2.2.1]HEPTANE | BASF Agro B.V. (NL) | 2025-12-24 | — | — | EP | disclosed |
| EP-3724193-B1 | PROCESS FOR PREPARING 2-EXO-(2-METHYLBENZYLOXY)-1-METHYL-4-ISOPROPYL-7-OXABICYCLO[2.2.1]HEPTANE | BASF AGRO BV (NL) | 2024-09-11 | — | — | EP | disclosed |
| CN-110337438-B | Process for the preparation of 2-exo- (2-methylbenzyloxy) -1-methyl-4-isopropyl-7-oxabicyclo [2.2.1] heptane | 巴斯夫农业公司 | 2024-03-26 | — | — | CN | disclosed |
| US-11897895-B2 | Process for preparing 2-exo-(2-Methylbenzyloxy)-1-methyl-4-isopropyl-7-oxabicy-clo[2.2.1]heptane | BASF Agro B.V. (NL) | 2024-02-13 | — | — | US | disclosed |
| US-11384093-B2 | Process for preparing 2-exo-(2-Methylbenzyloxy)-1-methyl-4-isopropyl-7-oxabicyclo[2.2.1]heptane | BASF Agro B.V. (NL) | 2022-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11897895-B2 | Process for preparing 2-exo-(2-Methylbenzyloxy)-1-methyl-4-isopropyl-7-oxabicy-clo[2.2.1]heptane | EXOC1, EXOC4, EXOC3 | MEN1 1997/4885KMT2A 2665/4885CYP2D6 413/4885 |
| US-11384093-B2 | Process for preparing 2-exo-(2-Methylbenzyloxy)-1-methyl-4-isopropyl-7-oxabicyclo[2.2.1]heptane | EXOC1, CYP8B1, EXOC3 | MEN1 1874/4885KMT2A 3452/4885CYP2D6 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.